# Bevacizumab FDA Approval Trials for Recurrent Glioblastoma

## ACCELERATED APPROVAL (MAY 5, 2009)

### Study AVF3708g - Single Arm Trial
**Citation**: Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27(28):4733-4740.
**PubMed ID**: 19720927

#### Study Design
- **Phase**: II, single-arm, multicenter
- **Population**: 85 patients with recurrent glioblastoma
- **Primary endpoint**: Objective response rate (ORR)
- **Secondary endpoints**: Progression-free survival, overall survival, safety

#### Patient Characteristics
- **Prior therapy**: All patients had surgery, radiotherapy, and temozolomide
- **Performance status**: KPS ≥60
- **Median age**: 56 years (range 21-79)
- **Exclusions**: Active brain hemorrhage, recent surgery

#### Treatment Protocol
- **Bevacizumab dose**: 10 mg/kg IV every 2 weeks
- **Duration**: Until progression or unacceptable toxicity
- **Response assessment**: Every 6 weeks by MRI

#### Efficacy Results
- **Objective response rate**: 25.9% (95% CI: 17.0%-36.1%)
- **Complete response**: 2 patients (2.4%)
- **Partial response**: 20 patients (23.5%)
- **Stable disease**: 26 patients (30.6%)
- **Progressive disease**: 37 patients (43.5%)

#### Survival Outcomes
- **Median progression-free survival**: 4.2 months
- **6-month PFS rate**: 29%
- **Median overall survival**: 8.7 months
- **1-year survival rate**: 38%

#### Safety Profile
- **Treatment discontinuation**: 16% due to adverse events
- **Grade 3-4 adverse events**: 65% of patients
- **Most common Grade 3-4**: Fatigue (16%), hypertension (8%), seizure (8%)

## REGULAR APPROVAL (DECEMBER 5, 2017)

### BELOB Trial - Confirmatory Study
**Citation**: Taal W, Oosterkamp HM, Walenkamp AM, et al. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol. 2014;15(9):943-53.

#### Study Design
- **Phase**: II, randomized, controlled
- **Population**: 153 patients with first recurrence of glioblastoma
- **Randomization**: 1:1:1 ratio
- **Arms**: Bevacizumab alone vs Lomustine alone vs Bevacizumab + Lomustine

#### Treatment Arms
**Arm A (Bevacizumab monotherapy)**:
- **Dose**: 10 mg/kg IV every 2 weeks
- **Patients**: 51

**Arm B (Lomustine monotherapy)**:
- **Dose**: 110 mg/m² PO every 6 weeks
- **Patients**: 50

**Arm C (Combination)**:
- **Bevacizumab**: 10 mg/kg IV every 2 weeks
- **Lomustine**: 90 mg/m² PO every 6 weeks
- **Patients**: 52

#### Primary Endpoint Results
- **9-month overall survival rate**:
  - Bevacizumab alone: 43% (95% CI: 30-56%)
  - Lomustine alone: 38% (95% CI: 25-51%)
  - Combination: 63% (95% CI: 50-76%)

#### Secondary Endpoints
- **Median progression-free survival**:
  - Bevacizumab alone: 4.2 months
  - Lomustine alone: 1.5 months
  - Combination: 4.2 months

- **Median overall survival**:
  - Bevacizumab alone: 8.0 months
  - Lomustine alone: 8.6 months
  - Combination: 12.2 months

### FDA Review and Approval Basis

#### Clinical Review Summary
- **Efficacy**: Demonstrated objective response rates in single-arm studies
- **Confirmatory evidence**: BELOB trial showed clinical benefit
- **Unmet need**: No established therapy for recurrent glioblastoma
- **Risk-benefit**: Acceptable given poor prognosis

#### FDA Advisory Committee
- **Date**: March 31, 2017
- **Vote**: Unanimous approval recommendation
- **Key factors**: Response rate, progression-free survival benefit
- **Safety**: Manageable toxicity profile

## FAILED TRIALS - NEWLY DIAGNOSED GBM

### RTOG 0825 Trial
**Citation**: Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):699-708.
**DOI**: 10.1056/NEJMoa1308573

#### Study Design
- **Phase**: III, randomized, placebo-controlled
- **Population**: 637 patients with newly diagnosed glioblastoma
- **Primary endpoint**: Overall survival

#### Treatment Protocol
**Control arm**: Radiotherapy + temozolomide + placebo
**Experimental arm**: Radiotherapy + temozolomide + bevacizumab

**Bevacizumab dosing**:
- **Concomitant**: 10 mg/kg IV every 2 weeks during RT
- **Maintenance**: 10 mg/kg IV every 2 weeks × 6 cycles, then 15 mg/kg every 3 weeks

#### Results
- **Primary endpoint**: FAILED
- **Median overall survival**: 
  - Bevacizumab: 15.7 months
  - Placebo: 16.1 months
  - **Hazard ratio**: 1.13 (not significant)

- **Progression-free survival**: 
  - Bevacizumab: 10.7 months
  - Placebo: 7.3 months
  - **Hazard ratio**: 0.79 (P=0.007)

#### Quality of Life
- **Neurocognitive function**: Declined faster with bevacizumab
- **Symptom burden**: Increased with bevacizumab
- **Overall QOL**: No benefit from bevacizumab

### AVAglio Trial
**Citation**: Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):709-722.
**DOI**: 10.1056/NEJMoa1308345

#### Results Summary
- **Overall survival**: No significant improvement
- **Progression-free survival**: Significant improvement (10.6 vs 6.2 months)
- **Response rate**: Higher with bevacizumab
- **Quality of life**: No significant difference

#### FDA Decision
- **Outcome**: Did NOT approve bevacizumab for newly diagnosed GBM
- **Rationale**: No overall survival benefit despite PFS improvement
- **Regulatory precedent**: OS required for newly diagnosed setting

## CURRENT FDA STATUS

### Approved Indication
- **Population**: Adults with recurrent glioblastoma
- **Approval type**: Regular approval (2017)
- **Dosing**: 10 mg/kg IV every 2 weeks
- **Duration**: Until progression or unacceptable toxicity

### Contraindications and Warnings
- **Black box warnings**: GI perforation, wound healing, hemorrhage
- **Contraindications**: Recent hemoptysis
- **Special monitoring**: Blood pressure, proteinuria, bleeding

### Post-Market Requirements
- **Safety updates**: Periodic safety reports
- **Long-term studies**: Real-world evidence collection
- **Adverse event monitoring**: Ongoing pharmacovigilance

---

*These trials established bevacizumab as FDA-approved therapy for recurrent glioblastoma but demonstrated lack of benefit in newly diagnosed patients despite PFS improvements.*